Trial tests targeted radiation plus immunotherapy after anti–PD-1 failure
Treatments studied
Part of Cancer, Infections clinical trials.
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older and can sign consent to join the study.
- You have confirmed Merkel cell cancer based on tumor tissue or cell testing.
- Your cancer scan (Ga-68 dotatate) shows somatostatin receptors, and you have at least one measurable tumor spot.
- Your Merkel cell cancer has gotten worse after treatment with an anti–PD-1/L1 antibody, and the worsening was documented within 12 weeks of your last dose.
- You were doing well physically at screening (ECOG 0–1) and your blood/organ tests meet safety thresholds.
- You must not have active serious infections or uncontrolled organ problems, and you can safely take the study treatment per the trial doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs—ASTX727 (an oral pill) and retifanlimab (an immunotherapy)—for people with advanced Merkel cell carcinoma that has grown despite previous immunotherapy. The goal is to see if this combination can work better than previous treatments.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests the combination of pembrolizumab (an immunotherapy) with standard chemotherapy (cisplatin or carboplatin plus etoposide) in people with advanced Merkel cell carcinoma who haven't had treatment before. The goal is to see if this combination improves outcomes.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.